Background The National Health Service (NHS) in England spends over £9 billion on prescription medicines dispensed in primary care, of which over two-thirds is accounted for by repeat prescriptions. Recently, GPs in England have been urged to limit the duration of repeat prescriptions, where clinically appropriate, to 28 days to reduce wastage and hence contain costs. However, shorter prescriptions will increase transaction costs and thus may not be cost saving. Furthermore, there is evidence to suggest that shorter prescriptions are associated with lower adherence, which would be expected to lead to lower clinical benefit. The objective of this study is to estimate the cost-effectiveness of 3-month versus 28-day repeat prescriptions from the perspective of the NHS. Methods We adapted three previously developed UK policy-relevant models, incorporating transaction (dispensing fees, prescriber time) and drug wastage costs associated with 3-month and 28-day prescriptions in three case studies: antihypertensive medications for prevention of cardiovascular events; drugs to improve glycaemic control in patients with type 2 diabetes; and treatments for depression.
Introduction
In England, over £9 billion is spent annually by the National Health Service (NHS) on prescription medicines dispensed in primary care [1] . Around two-thirds of this expenditure is accounted for by repeat prescriptions, which are issued by general practitioners (GPs) to treat chronic health conditions without the need for a patient consultation [2] .
Recent policy changes in some areas of England have advised GPs to reduce the duration of repeat prescriptions issued to patients with chronic health conditions, typically from 3 months to 28 days [3] [4] [5] [6] . The rationale for the policy change was to reduce medicine waste and thus generate cost savings. Published estimates, including those of the National Audit Office (NAO), suggest that up to £300 million of prescription medications are wasted in England each year, of which half may be avoidable [7, 8] . Nevertheless, the policy may have overlooked some potential disadvantages of shorter prescriptions, including additional transaction costs incurred by the NHS (e.g. through increased GP time to issue prescriptions and dispensing fees to pharmacists) and the inconvenience of additional trips to the pharmacy (which may lead to reductions in patient satisfaction and additional costs to patients, e.g. related to lost productivity) [9] [10] [11] [12] . Furthermore, the relationship between prescription duration and adherence to treatment (i.e. whether patients take their drugs as directed by their GP) should also be considered, since any detrimental impact on health, including the risk of adverse health events, would lead to increased healthcare costs in the longer term.
A recent systematic review identified consistent (but poor quality) evidence that longer prescription duration was associated with increased adherence but increased wastage [13] . An analysis of UK primary-care data confirmed the positive relationship between prescription duration and wastage [14] . However, this also showed that reductions in transaction costs associated with longer prescriptions more than compensated for the costs of increased wastage (at least in the case studies examined). The review [13] noted (1) a shortage of studies examining the longterm relationship between prescription duration and health outcomes (mean follow-up of previous studies was 20.3 months), (2) that existing studies were entirely US based and so of questionable relevance to the UK setting, (3) only one examined any impact on health outcomes [15] , and (4), there were no reported outcomes in terms of quality of life-years (QALYs) gained.
Therefore, the purpose of this paper is to estimate the longer-term costs and health consequences and hence incremental cost-effectiveness associated with 3-month and 28-day repeat prescriptions for patients with stable, chronic conditions requiring one or more repeat prescriptions in the primary-care setting.
Methods
We selected three case studies of drugs typically prescribed in primary care for chronic, stable conditions. These were (1) antihypertensive medications for prevention of cardiovascular events in patients with essential hypertension, (2) metformin to improve glycaemic control in patients with type 2 diabetes, and (3) selective serotonin reuptake inhibitors (SSRIs) for depression.
We first identified and then adapted existing decision analytic models used to assess the clinical-and cost-effectiveness of relevant pharmaceutical products by the National Institute for Health and Care Excellence (NICE). We then identified data on (1) the relationship between prescription length and adherence in patients with chronic health conditions (from the systematic review [13] ), (2) the relative treatment effects of the drugs versus placebo (where existing analyses did not compare versus placebo) (from relevant NICE guidance), (3) transactions costs (dispensing fees and prescriber time) and (iv) cost of drug wastage (from an analysis of UK primary-care data [14] ).
Models were adapted to calculate the expected cost and QALYs gained from 3-month or 28-day repeat prescriptions. A general overview is shown in Figure 1 ; the long-term cost and QALYs associated with a particular treatment were assumed to represent perfect adherence and those of placebo to represent zero adherence. Given that the systematic review [13] showed 3-month repeat prescriptions were associated with higher adherence than 28-day prescriptions, in the absence of evidence to the contrary, we assumed the 3-month repeat prescriptions would yield the expected cost and QALYs associated with perfect adherence (i.e. p = 1 in Fig. 1 ), and 28-day be equal to those multiplied by the relative risk of adherence. Plausible values for the relative risk for each of the three groups of commonly prescribed medications were extracted from studies identified in the systematic review that had Table 1 An overview of the methodological approach used in the three case studies

Stage 1
Appropriate decision models were identified. These had been used by NICE to assess the cost-effectiveness of relevant medications. The selected models are summarised in Table 2 Stage 2 Additional data was identified (if not already included in the original decision model) as follows:
(1) the relative treatment effects of treatment versus placebo (2) relationship between adherence and health consequences (3) relationship between prescription length and adherence (4) transaction costs (dispensing fees and prescriber time)
(5) cost of drug wastage These data are described for each case study in Table 3 Stage 3 The decision model was adapted. Drawing on the data identified in Stage 1, the input parameters and/or model outputs of the identified decision model were adjusted to account for different costs, QALYs and adherence associated with no treatment and treatment with different prescription duration Results Health consequences, costs, ICERs and incremental net benefit (INB) were reported for:
• treatment compared to placebo
• treatment with 3-month compared to 28-day prescription duration
The results for each case study are reported in Tables 4, 5 and 6 NICE National Institute for Health and Care Excellence, QALY quality-adjusted life years examined medications which could be reasonably categorised into those three groups [13] . Where there was more than one estimate, or a range of estimates, these were subsequently used in sensitivity analyses.
A summary of the methods used in each case study is provided in Table 1 . Incremental cost-effectiveness ratios (ICERs) were calculated (based on the incremental costs and QALYs of treatment with 3-month versus 28-day prescriptions). Net benefit and incremental net benefit (INB) were also reported. This assumes a threshold value of the decision-maker's willingness to pay for a QALY of £20,000 (the lower end of the cost-effectiveness threshold over which treatments are less likely to be recommended for use in the NHS) [16] . The perspective of the evaluation was costs to the NHS in England and all cost data are reported in 2015/2016 British Pounds Sterling. Costs were inflated when necessary to 2015/2016 levels using the Personal Social Services Research Unit (PSSRU) Hospital and Community Health Service indices [17] .
Specific methods for each case study follow, with summaries of the original source models provided in Table 2 , and of the identified data and key assumptions in Table 3 . Some additional details for is also provided in Appendices 1, 2 and 3 (Electronic Supplementary Materials). Health outcome QALYs which reflected prevention of cardiovascular events (non-fatal unstable angina, myocardial infarction, heart failure and stroke, and cardiovascular-related deaths) and side effects (onset of heart failure and diabetes)
QALYs which reflected the impact of treatment on the first occurrence of seven diabetes-related complications (fatal or non-fatal MI, other IHD, stroke, heart failure, amputation, renal failure and eye disease measured in terms of blindness in one eye) and death. All based on data from UKPDS RCT [34] QALYs (utility scores were based on a study by Sapin et al. 2004 ) [35] Key clinical input parameters
Baseline risks were identified from a range of sources [18] Treatment effects on HbA1c, weight, hypoglycaemic episodes and treatment drop-outs due to intolerance were taken from a clinical review network meta-analysis) [32] Odds and probabilities of drop-out (after 2-3 months), remission (after 8-9 months) and relapse (after 14-15 months) were identified in a literature review and through expert opinion (see Appendix Annual costs associated with each health state (from the NHS perspective), and the costs of medications, had been identified from various sources [e.g. British National Formulary (BNF)] and used as inputs in the model (Table 2) [18].
Stage 2: Identify Additional Data
In the systematic review [13] , two studies by Hermes et al 2010 and Taitel et al 2012, reported the relative risk of being adherent for longer versus shorter duration prescriptions for antihypertensive medications [19, 20] . No primary studies or decision models were identified examining the relationship between prescription length (or adherence) and health outcomes [13] . It was not necessary to identify additional input data on the costs and health consequences of zero adherence since the source model included a 'no treatment'/placebo comparator. The cost of dispensing fees identified from the latest NHS Drug Tariff [21] and the cost of prescriber time and drug wastage associated with different duration prescriptions for antihypertensive medications were identified in the analysis of UK primary care data (Table 3 ) [14] .
Stage 3: Adapt Existing Model
Modifications to the structure of the source model were not required as it already examined the costs and consequences of the main groups of antihypertensive interventions currently prescribed in general practice and included a 'no treatment' comparator. First, the model was replicated and run to assess the lifetime expected costs and QALYs associated with a weighted average of antihypertensive treatments and with placebo (i.e. representing 'perfect' adherence with antihypertensives and zero adherence as illustrated in Fig. 1) . As in the base-case analysis used in the source model, the cohort used in the analysis was based on a 65-year-old male with an annual cardiovascular disease risk of 2%, heart failure risk of 1% and diabetes risk of 1.1%. Second, we conducted two alternative analyses to incorporate different adherence levels associated with 3-month and 28-day prescriptions, described in more detail below.
Antihypertensives Versus 'No Treatment'
The source model estimated a cost of £5185 and 9.57 QALYs for 'no treatment'. A 'typical treatment' comparator was created as a weighted average of the costs and QALYs [19, 20] identified in systematic review [13] Studies by Hermes et al 2010 (RR = 0.891) and Taitel et al 2012 (RR = 0.863) [19, 20] identified in systematic review [13] Studies by Taitel et al 2012 (RR = 0.748) and Pfeiffer et al (RR = 0.542) [20, 24] identified in systematic review [13] (4) Transaction costs
Data reported in the analysis of UK primary care data [14] • In the first analysis, we assumed the costs and outcomes associated with 3-month prescriptions were equal to the cost and outcomes associated with 'weighted treatment', i.e. £4563 and 10.16 QALYs (to which the transaction and drug wastage costs were added). In the 28-day arm, the total costs and QALYs were a weighted average of the QALYs in the 'typical treatment' and the 'no treatment' comparators, as described in the Methods section. The weighted average was calculated using evidence from the studies by Hermes et al 2010 and Taitel et al 2012 on the relationship between prescription length and adherence, which reported relative risks of 0.92 and 0.85, respectively [19, 20] . We report analyses using both sources separately, as well as further analyses using the highest and lowest 95% confidence limits of the two sources (lowest lower bound, Taitel In the second analysis, instead of adjusting overall costs and QALYs, we adjusted the relative risks of the transition probabilities by the adherence. For example, the relative risk of MI assumed with 3-month prescriptions for beta- The second approach involved adjusting model inputs to account for different adherence levels (i.e. the relative treatment effects, vs no treatment, for each health state) blockers is 0.86 (Appendix 1, Table A2 ). The relative adherence with 28-day versus 3-month prescriptions is 0.85 [20] , so the relative risk of MI with 28-day prescriptions is 0.88 [= 1-(1 -0.86) 9 0.85].
Case Study 2: Metformin to Improve Glycaemic Control in Patients with Type 2 Diabetes
Stage 1 and 2: Identify Decision Model and Additional Data
Details of model and data identification (stages 1 and 2 of Table 1 ) are in Appendix 2.
Stage 3: Adapt Existing Model
We focused on the impact of different prescription lengths at the initial therapy stage (people failing to manage their condition on diet and exercise alone) comparing metformin with placebo (two of the seven comparators in the original model). Metformin was chosen for use in this case study as it is current first-line practice. The existing structure of the model and all model inputs remained unchanged, since the identified model already examined the costs and consequences of a wide range of pharmacological interventions for type 2 diabetes, which are currently prescribed in general practice in the UK.
Metformin Versus 'No Treatment' Lifetime costs
and QALYs for metformin, estimated using the original source model, were £19,900 and 9.033, respectively, compared with £20,722 and 8.912 for placebo (assumed to represent no treatment) (Table 5 ). Metformin therefore dominates placebo. These results were driven by higher risk of diabetes-related complications (including amputation, blindness, renal failure, heart disease and stroke) and higher treatment costs due to more rapid progression to later-stage intensification therapies (where patients received[1 non-insulin-based therapy) with placebo.
Three-Month Versus 28-Day Prescribing of Metformin
As per case study 1, we assumed 3-month prescriptions yielded equivalent costs and outcomes to the metformin treatment arm in the source model (i.e. p = 1 as per Fig. 1 ). To this was added additional annual transactional and drug wastage costs for 3.8 years, the period of time that the average patient received initial treatment (monotherapy, where metformin was the only antidiabetic drug). For the 28-day prescriptions, we took a weighted average of the costs and QALYs of the metformin and placebo arms according to the relative risk of being adherent reported by Hermes et al and Taitel et al, which were 0.891 and 0.863, respectively [19, 20] . These are reported as two separate scenario analyses. The total costs and QALYs for the 28-day prescriptions in the first scenario are calculated as 0.891 9 Metformin arm costs or QALYs ? 0.109 9 -placebo arm costs or QALYs. To these calculated total costs were added the additional transaction and drug wastage costs for the average initial treatment period (3.64 years in the first scenario). As per case study 1, we also explored the lower and upper 95% confidence limits (lowest lower bound, Taitel, RR = 0.851, highest upper bound Hermes, RR = 0.926).
Case Study 3: Selective Serotonin Reuptake
Inhibitors (SSRIs) for Depression
Stage 1 and 2: Identify Decision Model and Additional Data
Details of model and data identification (stages 1 and 2 of Table 1 ) are in Appendix 3.
Stage 3: Adapt Existing Model
In this case study, we maintained the overall model structure since the identified model had recently been updated by NICE in 2016 and already examined the costs and consequences of antidepressants currently prescribed in general practice. However, whereas the original treatment arms emanating from the decision node in the model were two comparable pharmacological interventions (or a pharmacological intervention with and without CBT), in our adapted model (Appendix 3, Fig. A3.1 ), we substituted instead 3-month and 28-day prescribing of a 'typical' SSRI. The unit cost data were based on a weighted average of the costs associated with ten (generic and branded) SSRIs.
The weighted average was calculated using unit cost data from the Prescription Cost Analysis (published by NHS England), which showed the total number of items dispensed in the community in 2014 for each group of medications [22] . For the 3-month and 28-day arms of the decision tree, we added the appropriate transaction and wastage costs to these (weighted average) SSRI unit costs.
The health consequence data for our 'typical' SSRI were based on data reported in the NICE clinical evidence review on the absolute risk of dropout, no remission and relapse for a placebo arm, and the relative risk for an escitalopram treatment arm. These data were used to calculate the probability nodes in the decision tree where the placebo arm represented our zero-adherence scenario and the escitalopram treatment arm represented our perfectadherence scenario (Appendix 3, Table A3 .1). Since the NICE guideline development group concluded that there was sufficient doubt about the clinical importance of differences between antidepressant treatments to not justify the development of recommendations for specific drugs [23] , we did not examine data on the relative efficacy of other antidepressants compared to escitalopram.
Replicating the approach taken by NICE using the source model, we reported the model outputs in terms of the total costs and QALYs of the two arms of the decision tree for two separate cohorts of 100 patients with moderate and severe depression (Table 6 ).
SSRIs Versus Placebo
For patients with moderate and severe depression, SSRI treatment was less costly (£1907.79 vs £2039.94 per patient in the case of moderate depression) than placebo with higher QALY gains (0.63 vs 0.61 in the case of moderate depression, Table 6 ). The INB per patient for moderate and severe depression was estimated at £467 and £529, respectively.
Three-Month Versus 28-Day Prescribing of
SSRIs As per the other case studies, costs and outcomes for the 3-month prescriptions are assumed to be the same as the treatment arm. Those for the 28-day treatment arm were calculated using a weighted average of the cost and QALYs associated with perfect and zero adherence (based on the evidence from studies on the relationship between prescription length and adherence identified in the systematic review [13] ).
Two relevant studies, by Pfeiffer et al [24] and Taitel et al [20] reported relative risks of 0.542 and 0.748, respectively. We reported results with these point estimates separately, as well as at the lowest lower 95% confidence limit (Pfeiffer, RR = 0.540) and highest higher limit (Taitel, RR = 0.780) to define a plausible range of ICERs and INB.
Results
In all three case studies for all scenarios, longer prescriptions were both cost-saving and led to higher QALYs gained. In case study 1 (antihypertensives), the INB per patient ranged from £1470 to £2571 (Table 4 ). In case study 2 (metformin), 3-month prescriptions were less costly and yielded higher QALYs than 28-day prescriptions, with expected INB per patient of between £312 and £555 (Table 5) . Finally, in case study 3 (SSRIs), for both moderate and severe depression, the ICERs remained negative (3-month prescriptions were cost saving and QALY-enhancing). The INB per patient ranged between £378 and £496 for moderate depression and £427 and £560 for severe depression.
Discussion
Principal Findings
The main finding was that longer, 3-month repeat prescriptions, are associated with lower lifetime costs and higher QALYs when compared with shorter, 28-day prescriptions. The main driver for this finding was improved adherence in the 3-month scenarios, which was grounded in the evidence from all studies of the relationship between prescription duration and adherence identified in the systematic review [13] . The lower transaction and drug wastage costs reported in the analysis of primary care data [14] also contributed to the finding. Although these immediate cost savings are smaller in magnitude than the longer-term benefits arising from improved adherence, they might nonetheless be more pertinent to those making prescribing decisions. Furthermore, it is probable that patients would favour longer prescriptions, at least from the perspective of limiting the frequency of pharmacy visits.
As a result, 3-month prescriptions dominate 28-day prescriptions, with positive INB associated with the 3-month prescriptions. For example, the plausible range of INB (to the NHS) per patient with hypertension receiving treatment for the secondary prevention of cardiovascular events was £1575 to £2571. Data from the Health Survey for England show that 14% of men and 15% of women are currently prescribed antihypertensives specifically for hypertension [25] . Thus, there may be significant potential for (long-term) cost savings and health gain if these patients were routinely issued 3-month duration repeat prescriptions. This finding was consistent across all three case studies, despite differences in the nature of the treatments. Whereas two case studies focused on the prevention of future ill-health (e.g. cardiovascular events), increased adherence reduced the expected costs of health complications later in life, the other case study examined SSRI treatment for moderate and severe depression, a chronic or episodic condition. In this case, lower healthcare costs were associated with longer duration prescriptions due to reductions in, for example, the likelihood of requiring additional care during the initial treatment phase as a hospital inpatient.
Our remit was to explore the implications of longer prescription lengths for chronic stable disease. Such treatments tend to be dominant (both less expensive and yielding greater QALYs) compared with placebo as they tend to be low-cost drugs with potential to prevent significant life-changing events such as MI or stroke in the future. This was indeed the case in our three studies. For non-dominant examples, as long as perfect adherence is cost-effective, any partial adherence will also be cost-effective conditional on a linear dose/response relationship. Exploration of this is beyond the scope of this analysis, but drugs requiring close to perfect compliance for any effect to be observed are unlikely to be suitable for longer prescriptions on cost-effectiveness grounds.
Comparison with Existing Studies
In a recent economic evaluation of a pharmacist-led intervention, which supports people starting new medications for long-term conditions, decision analytic models were used to assess the lifetime cost and health consequences arising from improved adherence [26] . However, to the best of the authors' knowledge this is the first study to use decision modelling to assess the impact of prescription duration on longer-term costs and QALYs.
A number of other observational studies have examined the cost impact of different prescription lengths. A negative relationship between costs and prescription length was found in four of five studies identified [20, [27] [28] [29] but the relationship arose for different reasons. The four observing a negative relationship had examined the costs (to thirdparty payers in the US) over a short time horizon. The cost savings arose from reductions in administrative costs of prescribing medication (e.g. dispensing fees). However, these studies did not account for changes in wider healthcare expenditure which would result, particularly in the longer term, from the changes in health status associated with different adherence levels.
The fifth identified study did include those wider costs and showed a positive relationship between prescription length and costs [30] . One explanation could be that healthcare expenditures were examined only over a short time horizon, whereas (two of) the case studies presented in this article examined lifetime costs, focusing on prevention of future cardiovascular events. It should also be noted that all the previous studies were US based and generally from a particular payer's perspective (e.g. Veterans Affairs or Medicaid), which may not be directly comparable to the UK setting.
Limitations
The three case studies presented in this article are based on relatively straightforward adaptions of existing, good quality decision models, all of which have been used to inform policy in the recent past. We chose these models (rather than conducting a systematic review of other models) as they, by definition, met NICE's quality criteria and had already been used to inform policy. Basing our analyses on these models thus ensured the case studies were comparable with NICE guidance and hence most policy relevant. Limitations inherent in the specific models are discussed in full detail in the respective guidelines. Therefore, the remainder of this section addresses limitations related to the model adaptations, which were made in this study.
First, our findings rely on the positive relationship between prescription length and adherence, which was based on studies identified in a systematic review [13] . Whilst all the evidence was consistent, the studies were observational, rather than randomised experimental studies, and so are at high risk of bias.
Second, in the absence of data to the contrary, the model adaptations relied on two key assumptions: (1) treatment effects observed in model active and placebo (no treatment) arms of clinical trials were assumed to represent the maximum effect comparing perfect and zero adherence and (2) a linear dose-response curve was assumed; thus 50% adherence would generate 50% of the treatment effect. However, since we consistently identified a positive INB associated with longer prescription durations, any change in these assumptions would affect only the magnitude of QALY gains, cost savings and INB. The likelihood that longer prescriptions represent a cost-effective choice would not be affected.
Third, as is common in all decision models which include a 'no treatment' arm, it was necessary to assume that health outcome data from the 'placebo' arm of clinical trials is equivalent to 'no treatment.' However, the placebo effect may lead to an overestimation of the QALYs associated with no treatment. Consequently, the health gain arising from increased adherence in longer prescription durations may have been underestimated.
Other limitations were that we assumed adherence was constant over the period of the analysis, and whilst the study took an NHS perspective, any revenue due to the NHS from prescription charges was excluded. However, patients with diabetes are exempt from the prescription charge, and almost 90% of prescriptions dispensed in the community in England do not attract any charge, therefore any revenue would be minimal and thus unlikely to change the results of this study [31] .
Conclusion
The finding that longer prescriptions may be cost saving to the NHS indicates that the recent policy of encouraging GPs to prescribe 28-day duration prescriptions is not supported by the evidence. Whilst this study accounted for the cost savings from reduced medicine waste associated with 28-day prescription duration, these short-term savings were outweighed by additional transaction and drug wastage costs and longer-term healthcare costs arising from reduced adherence. However, our results must be considered with due caution as they rely on the evidence suggesting a positive association between prescription length and adherence; the observational nature of the studies means they are at high risk of bias. In order to identify an optimal prescription length, the exact nature of this relationship needs further examination (not least since it is unlikely to be linear or constant between different populations and disease areas). Hence, we suggest implementing different duration prescriptions within, for example, a steppedwedge cluster randomised controlled trial design to inform a more rigorous assessment of the costs and/or (short-term) health impacts of different duration prescriptions.
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